AHA Dec. 22 filed a friend-of-the-court brief in support of a Louisiana law that prohibits drug companies from denying Louisiana hospitals the same 340B discounts for drugs dispensed at community pharmacies that would be provided via in-house pharmacies.

PhRMA and AstraZeneca challenged the state law as preempted by the federal law that created the 340B program, and AHA asserts that their challenge should be rejected.

“PhRMA and AstraZeneca cannot demonstrate that Congress intended to create or occupy any field through its 340B legislation,” the brief states. “Nor does Louisiana law conflict with the federal 340B statute. In reality, it furthers Congress’ goal in enacting the 340B program: to enable hospitals to ‘stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.’”

AHA was joined in filing the amicus brief by the Louisiana Hospital Association, the Rural Hospital Coalition and 340B Health.

Related News Articles

Headline
A U.S. district court judge for the District of Columbia May 15 ruled the Department of Health and Human Services must preapprove the use of 340B “rebate…
Headline
The AHA May 14 filed an amicus brief in the U.S. District Court for the District of South Dakota in defense of the state’s 340B contract pharmacy law…
Headline
The AHA May 9 urged the Department of Health and Human Services to deny drug companies’ requests to approve their unlawful 340B rebate models. “The 340B…
Headline
The AHA May 8 filed an amicus brief in the U.S. District Court for the District of Nebraska in defense of the state’s 340B contract pharmacy law prohibiting…
Headline
The AHA May 1 expressed concerns to the Centers for Medicare & Medicaid Services about the payment process established under the Medicare Drug…
Headline
Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy, M.D., R-La., today released a report detailing findings from an investigation…